Randomized Controlled Trial of Patient Self-Testing of Warfarin Therapy Using an Internet Based Expert System
试验速览
- 阶段
- 4 期
- 入组人数
- 163
- 试验地点
- 1
- 主要终点
- The primary outcome variable used to assess therapeutic efficacy and safety will be the difference in TTR during the six months of AMS management and the six months of PST
研究概览
简要总结
To test the hypothesis that home international normalised ratio (INR) monitoring with supervised patient self-testing (PST)can provide comparable or superior time in therapeutic range (TTR) to that provided by traditional outpatient anticoagulation.
详细描述
Indications for anticoagulant treatment to prevent thromboembolic disease have increased in recent years. INR must be monitored frequently to determine the safest dose and to minimize the risk for thrombotic and haemorrhagic complications. Standard warfarin therapy is associated with rates of major haemorrhage of up to 5-9% annually and recurrent venous thromboembolism of up to 8%. These event rates are dependent of the model of care used to manage warfarin therapy, with better outcomes associated with home testing of the INR which enables patients to monitor their response to warfarin more frequently. INR results must still be 'managed' by communicating the data to the healthcare provider, usually be telephone or fax.
In this study we will evaluate a novel method of PST; supervised PST with an internet based expert system, which 'manages' patients on oral anticoagulation by utilizing clinical and laboratory data provided by the patient and dose adjustment and retesting algorithms derived from clinical practice. Patients will be randomized to either 6 months of supervised PST or routine medical care by the AMS. At the end of the 6 month period, each patient will then 'cross over' to the other management regimen and the difference in TTR between the two periods will be compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •on warfarin therapy for a minimum of 2 months
- •are expected to be on warfarin therapy for the duration of the 12 month study
- •internet access
排除标准
- •inability to provide informed consent
- •inability to use a home INR meter
- •patients who do not have a telephone
- •more than 2 missed clinic appointments in the preceding 6 months
- •patients on anticoagulant drugs other than warfarin (eg heparin, low molecular weight heparin)
- •history of hemorrhagic complications with a therapeutic or therapeutic INR in the preceding 6 months
- •inability to attend the hospital at short notice, if necessary
研究组 & 干预措施
1
6 months of supervised patient self testing using an expert system
干预措施: CoaguChek (Patient self testing) (Device)
2
6 months of routine medical care by the anticoagulation management service
干预措施: Anticoagulation Management Service (AMS) (Device)
结局指标
主要结局
The primary outcome variable used to assess therapeutic efficacy and safety will be the difference in TTR during the six months of AMS management and the six months of PST
时间窗: 1 year
次要结局
- To compare the number of adverse events (haemorrhagic and thromboembolic) using PST and AMS management(1 year)
